NASDAQ:RXDX Prometheus Biosciences (RXDX) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free RXDX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$199.60▼$199.9850-Day Range$192.50▼$199.9252-Week Range$23.27▼$199.98Volume1.86 million shsAverage Volume913,102 shsMarket Capitalization$9.56 billionP/E RatioN/ADividend YieldN/APrice Target$200.00 Stock AnalysisStock Analysis Get Prometheus Biosciences alerts: Email Address Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Prometheus Biosciences Stock (NASDAQ:RXDX)Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.Read More Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about RXDX Stock News HeadlinesMarch 6, 2024 | benzinga.comCormorant Private Healthcare Fund III LP's Net WorthMay 30, 2023 | seekingalpha.comPrometheus Biosciences: 8.5% IRR And Closing In A MonthApril 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…May 28, 2023 | fool.comPrometheus Biosciences (NASDAQ: RXDX)May 23, 2023 | msn.comPrometheus Biosciences gains after HSR waiting for sale to Merck expiresMay 23, 2023 | barrons.comSHAREHOLDER ALERT: Weiss Law Investigates Prometheus Biosciences, Inc.May 18, 2023 | finance.yahoo.comWhat Makes Prometheus Biosciences (RXDX) an Attractive Investment Choice?May 12, 2023 | finance.yahoo.comPrometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?April 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…May 11, 2023 | msn.comJefferies Downgrades Prometheus Biosciences (RXDX)May 11, 2023 | msn.comRBC Capital Maintains Prometheus Biosciences (RXDX) Sector Perform RecommendationMay 9, 2023 | yahoo.comPrometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate ProgressMay 1, 2023 | msn.comAbbvie, Bristol Myers competed with Merck in sale of Prometheus - reportApril 29, 2023 | finance.yahoo.comWith 67% ownership, Prometheus Biosciences, Inc. (NASDAQ:RXDX) boasts of strong institutional backingApril 21, 2023 | finance.yahoo.comPharma Stock Roundup: JNJ Beats on Q1 Earnings, MRK to Buy RXDX & Other UpdatesApril 20, 2023 | finance.yahoo.comWhy Prometheus Biosciences Stock Is Skyrocketing This WeekApril 18, 2023 | markets.businessinsider.comRBC Capital downgrades Prometheus Biosciences (RXDX) to a HoldApril 18, 2023 | finance.yahoo.comPrometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?April 18, 2023 | finance.yahoo.comHow to Tell Biotech’s Likely Winners From LosersApril 17, 2023 | benzinga.comLooking At Prometheus Biosciences's Recent Unusual Options ActivityApril 17, 2023 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Prometheus Biosciences, Inc. (RXDX)April 17, 2023 | finance.yahoo.comPrometheus (RXDX) Stock Surges 70% on Buyout Offer From MerckApril 17, 2023 | barrons.comMerck’s Deal for Prometheus Expected to Generate Billions in Additional SalesApril 17, 2023 | msn.comMerck Acquires Prometheus Biosciences for $10.8 BillionApril 17, 2023 | finance.yahoo.comMerck/Prometheus: Big Pharma must swallow bigger premiumsApril 17, 2023 | finance.yahoo.comHealthcare Is Back. But Is It Here to Stay?April 17, 2023 | investorplace.comRXDX Stock Alert: The $10.8 Billion Reason Prometheus Biosciences Is Surging TodaySee More Headlines Receive RXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2023Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:RXDX CUSIPN/A CIK1557421 Webignyta.com Phone858-422-4300FaxN/AEmployees97Year Founded1995Price Target and Rating Average Stock Price Target$200.00 High Stock Price Target$200.00 Low Stock Price Target$200.00 Potential Upside/Downside+0.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,750,000.00 Net Margins-3,768.76% Pretax Margin-3,768.76% Return on Equity-33.50% Return on Assets-29.59% Debt Debt-to-Equity Ratio0.04 Current Ratio37.56 Quick Ratio37.56 Sales & Book Value Annual Sales$6.81 million Price / Sales1,403.55 Cash FlowN/A Price / Cash FlowN/A Book Value$16.12 per share Price / Book12.40Miscellaneous Outstanding Shares47,810,000Free Float46,187,000Market Cap$9.56 billion OptionableNot Optionable Beta-0.49 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Mark C. McKenna (Age 43)Pres, CEO & Chairman Comp: $1.33MDr. Keith W. Marshall M.B.A. (Age 55)MBA, Ph.D., Chief Financial Officer Comp: $829.45kMr. Mark Stenhouse (Age 56)Chief Operating Officer Comp: $807.4kDr. Olivier Laurent Ph.D. (Age 51)Chief Scientific Officer & Head of R&D Ms. Noel KurdiVP of Investor Relations & CommunicationsMr. Timothy K. Andrews Esq. (Age 44)Gen. Counsel & Sec. Ms. Nori Ebersole (Age 59)Chief People Officer Dr. Allison Luo M.D. (Age 50)Chief Medical Officer Dr. Thierry Dervieux DABCC (Age 55)Ph.d., Pharm.d., Chief Devel. Officer of Diagnostics & Medical Laboratory Director Mr. Chris DoughtyChief Bus. OfficerMore ExecutivesKey CompetitorsBio-TechneNASDAQ:TECHQiagenNYSE:QGENRepligenNASDAQ:RGENTenet HealthcareNYSE:THCHenry ScheinNASDAQ:HSICView All Competitors RXDX Stock Analysis - Frequently Asked Questions Should I buy or sell Prometheus Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" RXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXDX, but not buy additional shares or sell existing shares. View RXDX analyst ratings or view top-rated stocks. What is Prometheus Biosciences' stock price target for 2024? 1 Wall Street research analysts have issued 1 year price targets for Prometheus Biosciences' stock. Their RXDX share price targets range from $200.00 to $200.00. On average, they anticipate the company's share price to reach $200.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price. View analysts price targets for RXDX or view top-rated stocks among Wall Street analysts. How were Prometheus Biosciences' earnings last quarter? Prometheus Biosciences, Inc. (NASDAQ:RXDX) posted its quarterly earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.06. The biopharmaceutical company had revenue of $1.11 million for the quarter, compared to analyst estimates of $0.46 million. Prometheus Biosciences had a negative trailing twelve-month return on equity of 33.50% and a negative net margin of 3,768.76%. The business's revenue for the quarter was down 71.8% on a year-over-year basis. What other stocks do shareholders of Prometheus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD). When did Prometheus Biosciences IPO? Prometheus Biosciences (RXDX) raised $126 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO. Does Prometheus Biosciences have any subsidiaries? The following companies are subsidiares of Prometheus Biosciences: Prometheus Laboratories Inc..Read More This page (NASDAQ:RXDX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prometheus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.